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Abstract
Background: Aiming to answer the broad question ‘‘When does mutation occur?’’ this study examined the time of
appearance, dominance, and completeness of in vivo Gag mutations in primary HIV-1 subtype C infection.
Methods: A primary HIV-1C infection cohort comprised of 8 acutely and 34 recently infected subjects were followed
frequently up to 500 days post-seroconversion (p/s). Gag mutations were analyzed by employing single-genome
amplification and direct sequencing. Gag mutations were determined in relation to the estimated time of seroconversion.
Time of appearance, dominance, and completeness was compared for different types of in vivo Gag mutations.
Results: Reverse mutations to the wild type appeared at a median (IQR) of 62 (44;139) days p/s, while escape mutations from
the wild type appeared at 234 (169;326) days p/s (p,0.001). Within the subset of mutations that became dominant, reverse
and escapemutationsappearedat54(30;78)days p/sand104 (47;198)daysp/s,respectively (p,0.001).Amongthemutations
that reached completeness, reverse and escape mutations appeared at 54 (30;78) days p/s and 90 (44;196) days p/s,
respectively (p=0.006). Time of dominance for reverse mutations to and escape mutations from the wild type was 58 (44;105)
days p/s and 219 (90;326) days p/s, respectively (p,0.001). Time of completeness for reverse and escape mutations was
152 (100;176) days p/s and 243 (101;370) days p/s, respectively (p=0.001). Fitting a Cox proportional hazards model with
frailties confirmed a significantly earlier time of appearance (hazard ratio (HR): 2.6; 95% CI: 2.3–3.0), dominance (4.8 (3.4–6.8)),
and completeness (3.6 (2.3–5.5)) of reverse mutations to the wild type Gag than escape mutations from the wild type. Some
complex mutational pathways in Gag included sequential series of reversions and escapes.
Conclusions: The study identified the timing of different types of in vivo Gag mutations in primary HIV-1 subtype C infection
in relation to the estimated time of seroconversion. Overall, the in vivo reverse mutations to the wild type occurred
significantly earlier than escape mutations from the wild type. This shorter time to incidence of reverse mutations remained
in the subsets of in vivo Gag mutations that reached dominance or completeness.
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Introduction
Knowledge of early events in infection is essential for
understanding HIV-1 pathogenesis. Although correlates of
protection in HIV-1 infection are still elusive, it is widely believed
that the breadth of immune response plays an important role in
disease outcome, and is likely to be associated with the breadth of
viral mutational pathways. In natural HIV-1 infection, viral
mutational pathways that are not directly related to ART are still
poorly understood. This is because in most studies the time of
infection is rarely available, which makes synchronizing viral
mutations extremely difficult. In contrast, when the time of
infection or seroconversion can be reliably identified [1–4], the
time course of these mutations relative to infection or seroconver-
sion can be established. To date, surprisingly little attention has
been devoted to the timing of viral mutations in the natural course
of HIV infection. It is likely that knowledge of timing constraints
on viral mutations could shape preventive and therapeutic
strategies by identifying optimal times of intervention.
Viral escape mutations in the natural course of HIV infection
have been extensively studied [3–16], and were primarily
associated with virus-specific CD8+ T cell responses. A recent
report by Goonetilleke at al. [17] provided evidence that the T cell
responses to transmitted virus can occur very early, and are
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7727accountable for escape mutations during the drop of viral load
peak in the acute phase of HIV infection. Escape mutations
accumulated over the course of HIV infection can revert to HIV-1
consensus upon transmission to a new host with a different genetic
makeup. In the absence of immune pressure, reverse mutations to
the HIV-1 subtype consensus are assumed to restore viral fitness
that was apparently reduced due to escape mutations in the
previous host. It is believed that reverse mutations to subtype
consensus are widely observed during the early phase of HIV-1
infection [2,13,15,18,19], although quantitative and timing
relationships between reverse and escape mutations are uncertain.
In particular, little is known about the transient nature of HIV-1
mutations.
HIV-1 Gag is one of the most attractive targets for vaccine design,
as it is able to induce potent virus-specific T cell responses associated
with control of viral replication, lower viral set point, and more
favorable disease prognosis [20–32]. The timing of viral mutational
pathways and the impact of specific time of viral mutations on virus-
specific T cell responses are still unclear. Therefore, a better
understanding of viral mutational pathways in Gag and their temporal
constraints may advance rational design of an HIV-1 vaccine.
To address the question of when in vivo Gag mutations occur, we
focused on examining the time of appearance, dominance,
completeness, and loss of different types of viral mutations in
Gag soon after seroconversion over the first year of HIV-1 subtype
C infection in a cohort of 42 subjects with estimated time of
seroconversion. Such information may be useful in the design of
comprehensive immunologic studies, and set the stage for future
studies aimed at analysis of adaptive immune responses causing or
responding to viral mutations.
Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Boards of Botswana and the Harvard School
of Public Health. All patients provided written informed consent
for the collection of samples and subsequent analysis.
Study Subjects
Subjects with acute and recent HIV infection were enrolled in a
primary HIV-1 subtype C infection cohort in Botswana [33,34]
from April 2004 to April 2008. Forty-two subjects included 8
acutely infected (Fiebig stage II) and 34 recently infected (Fiebig
stage IV or V) individuals (Figure 1). Time of seroconversion (time
Figure 1. Time points of sampling (open squares) and sequencing (filled squares) in the study. A time scale is set to the estimated time
of seroconversion as time 0. The sampling time points were limited to 500 days p/s. The study subjects’ code is shown in the column at the left.
Acutely infected subjects are highlighted. Ten subjects who initiated ART are delineated by gray bars and arrows on the right.
doi:10.1371/journal.pone.0007727.g001
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between the last seronegative test and the first seropositive test
(within a week in most cases), and for recently infected subjects by
Fiebig staging [35]. Details on assignment of Fiebig stage are
described elsewhere [36] and provided in Figure S1. The cohort
included 9 male (2 acute) and 33 female (6 acute) participants. The
median age at enrollment was 27 years (IQR 25–32, range 20–56).
All subjects were Botswana nationals, and all infections were
HIV-1 subtype C [34,37]. Viral load and CD4+ T cell counts were
assessed during follow-up [33,34,37]. The median follow up
period was 378 (IQR 321–447) days post-seroconversion (p/s).
ART was initiated in 10 of 42 (24%) subjects within the observed
period of time due to a drop in CD4+ T cells.
Single-Genome Amplification and Sequencing
Previous studies showed comparability of the HIV-1 sequences
originated from cell-associated proviral DNA and viral RNA from
plasma [1,38]. In this study both viral RNA from plasma and cell-
associated proviral DNA were used as sources of templates for
amplification of viral sequences. Viral RNA was isolated from
plasma by QIAamp viral RNA Mini kit or QIAamp UltraSens
Virus kit (Qiagen, Valencia, CA). The proviral DNA was isolated
from buffy coats or PBMC by QIAamp DNA Mini kit (Qiagen,
Valencia, CA). The cDNA synthesis was performed using the
Transcriptor First Strand cDNA Synthesis kit (Roche Diagnostics,
Indianapolis, IN) and minus-strand primer gagDrev[39] (59- AAT
TCC TCC TAT CAT TTT TGG; HXB2 nucleotide positions
2,382 to 2,402). Both cDNA and DNA templates were subjects for
single-genome amplification by limiting dilutions [40,41] with
some modifications. The analyzed region of gag corresponded to
nucleotide positions 841 to 2,217 of HXB2 (amino acids 18 to 476
in relation to the Gag CDS in HXB2). FastStart High Fidelity
Enzyme Blend (Roche Diagnostics, Indianapolis, IN) was used in
both rounds of PCR. Primers F2NST [42] (59-GCG GAG GCT
AGA AGG AGA GAG ATG G; HXB2 nucleotide positions 769
to 793) and 1448L (59-AGG GGT CGC TGC CAA AGA GTG
ATT; HXB2 nucleotide positions 2,258 to 2,291) were used in the
1
st round PCR. Primers gag-5U (59-GTG CGA GAG CGT CAA
TAT TAA GAG; HXB2 nucleotide positions 794 to 817) and
1445L (59-GGT CGC TGC CAA AGA GTG ATT; HXB2
nucleotide positions 2,258 to 2,278) were used in the 2
nd round
PCR. Amplicons from dilutions with fewer than 30% positive
reactions were purified by Exo-SAP [43], and were sequenced
directly at both strands on the ABI 3730 DNA Analyzer using
BigDye technology. Sequence contigs were assembled by SeqS-
cape v.2.6. Multiple sequence alignment was performed by HIV-
align at the Los Alamos HIV Database site (http://www.hiv.lanl.
gov/) using the hidden Markov model and the codon-alignment
option followed by minor manual adjustments in BioEdit [44].
The obtained sequences were tested by HYPERMUT v.2.0
[45] and hypermutated sequences were excluded from analysis.
The median analyzed viral quasispecies in Gag (IQR) was 58.5
(42.0; 72.8) per subject, and 11.1 (8.8; 13.6) viral sequences per
time point per subject. Sequences from ARV-treated subjects were
included in the analysis and their corresponding time points are
shown by gray bars in Figure 1. The number of gag sequences per
time point per patient indicating the number of RNA and DNA
sequences generated in the study is presented in Figure S1. The
relatively limited number of sequenced quasispecies does not allow
us to exclude potential artifacts of sequencing, and it is possible
that at least some transient or minor mutations observed in this
study are not true mutations. To address the potential similarity
between RNA and DNA in primary HIV infection the
phylogenetic relationships between RNA and DNA sequences
obtained from the same sampling time points were analyzed. We
found no evidence for independent clustering, and the pattern of
intermingling between analyzed RNA and DNA sequences was
overwhelming (data not shown). Therefore, we included both
RNA and DNA sequences in the analysis.
Transmitted Viruses
To determine multiplicity of infection we used the methodology
described by Keele et al. [46], and found that 12 out of 42 cases
(29%; including one acutely infected subject) were likely to be
infected with distinct viral variants as evident by the maximum
achievable gag diversity of more than 1% and maximum
achievable number of differences (Hamming distances) of 14 or
more. A subset of 7 subjects (17%; including 2 acutely infected
subjects) were likely to be infected with a few closely related
variants. Thus, 30 out of 42 subjects (71%) in this study were
infected with a single or closely related viral variants.
Frequency of Viral Quasispecies
This study was focused on non-synonymous substitutions in Gag
only at time points presented in Figure 1 (and outlined in Figure
S1). The frequencies of translated amino acid sequences were
analyzed using MargFreq [47] per time point per subject. The
frequency of each amino acid was expressed as a fraction of 1 in
the pool of viral quasispecies at a given time point. Evolution of
amino acid frequencies was plotted over time in relation to the
estimated time of seroconversion as time 0. Dynamics of in vivo
Gag mutations was the primary focus of this study. Any change in
the proportion of amino acid(s) in the pool of viral quasispecies
over time was treated as mutation. At each analyzed amino acid
residue, we focused only on the amino acid with increasing
proportion in the pool of viral quasispecies over time. Therefore,
frequency changes in the pool of viral quasispecies over time were
tracked according to the following criteria based on their presence
in the earliest available sample. Sites with a single amino acid
present in the pool of the earliest available quasispecies were
examined for appearance of any alternative amino acid over the
time of follow up, and the new amino acid was subject to
evaluation. For example, according to the viral dynamics at Gag
position 242 in Figure 2A, only Thr was present in the pool of viral
quasispecies at the earliest time point at 7 days p/s (and also at day
70 p/s and day 98 p/s), while the first appearance of alternative
Asn was observed at day 203 p/s. Therefore, the kinetics of Asn
was a subject for evaluation at this site. In contrast, if multiple
amino acids were present in the pool of the earliest available
quasispecies, the amino acid that showed increase in its frequency
over time was a subject for analysis. For example, due to the
dynamics of viral mutations at Gag position 278 in Figure 2C, Ser
was a subject for evaluation and analysis. The evolution of amino
acid frequencies was plotted over time in relation to the estimated
time of seroconversion as time 0.
Types of Amino Acid Substitutions in Gag
The main focus of the study was on the time from estimated
seroconversion necessary to reach a specific state of viral mutation.
All observed mutations were included in the analysis. States of
viral mutations in Gag were analyzed at each amino acid position
over time, and classified by (i) their relation to wild type virus
(subtype consensus), (ii) fraction in the pool of viral quasispecies,
and (iii) presence at earliest time point. The most common viral
variant circulating within the given host population, or wild type,
is assumed to be the optimally fit virus which is commonly
expressed as an HIV-1 subtype consensus sequence [13,17,48,49].
The term wild type virus corresponds to HIV-1 subtype C
Gag Mutation Timing in HIV-1C
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from the wild type are classified as potential escape mutations, and
appropriate validation by immunological assays might be
necessary to prove their escaping nature. Two types of escape
mutation were distinguished: escape from the wild type (Figure 2A,
position 242), and escape from non-wild type (Fig. 2A, position
28). A mutation toward the wild type was considered a reverse
mutation, or reversion (Figure 2A, position 302).Two meanings of
Figure 2. Types of analyzed amino acid substitutions in the pool of viral quasispecies over time. A: Viral mutations by their relationship
to HIV-1 wild type. Number at the top of each graph indicates amino acid position in Gag, and is followed by frequencies of observed amino acids in
the extended HIV-1 subtype C consensus. Dynamics of Asn at amino acid position 242 represents escape mutation from the wild type virus, and is
delineated by circled E with arrow. Kinetics of Lys at position 302 demonstrates reverse mutation to the wild type virus. Viral mutation at position 28,
Arg-to-Lys substitution, occurs without involvement of the wild type virus, and therefore, is interpreted as escape from non-wild type. B: Viral
mutations by their fraction in the pool of viral quasispecies are classified as minor (position 186), dominant (position 114), complete (position 370), or
transient (position 419). Number at the top of each graph stays for the amino acid position in Gag followed by the most common amino acids in the
HIV-1 subtype C consensus, which is used to identify escape from and reversions to wild type virus. Circled letters with arrows indicate reverse
mutations to and escape mutations from HIV-1 subtype C wild type. C: Viral mutations by their presence in the earliest pool of viral quasispecies are
classified as de novo mutation (position 146), or pre-existing mutation (position 278). Circled letters with arrows indicate escape or reverse mutations.
doi:10.1371/journal.pone.0007727.g002
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The narrow definition of the term reverse mutation denotes reversion
to the ancestral state of transmitted virus, and applies to a limited
number of hosts linked by virus transmission. Examples of the
narrow use of the term include but are not limited to traceable
chains of viral transmission (e.g., confirmed donor–recipient pairs in
the case of HIV-discordant couples), or cases where transmitted
viruscanbereliablyreconstructedduetoearlysampling(e.g.,Fiebig
stage I or II) and series of in vitro experiments. The second, broader
definition of the term reverse mutation, which is widely used in
molecular epidemiology studies addressing viral evolution on the
population level, stands for reversion to the wild type virus in the
absence of immune pressure upon transmission to a new host
[2,4,48,50,51]. This definition relies on several assumptions
postulated in a series of recent studies [2,13,15,16,18,19,49,52,53]
including the following: i) the wild type virus corresponds to HIV-1
subtype consensus sequence; ii) the wild type virus is the most fit
viral variant, at least in the local epidemic environment; iii) escape
mutation(s) in the previous host occurred before transmission to a
new host; iv) reverse mutation represents a restoration of viral fitness
in the absence of immune pressure; and v) a mis-match of genetic
background between previous and new hosts is expected,
particularly in the profile of MHC class I HLA alleles. The second
definition of the term reverse mutation, denoting mutationtowardHIV
subtype consensus, is used throughout the current study.
Based on the frequency of specific amino acids in the pool of
viral quasispecies, we distinguished minor (Figure 2B, position 186),
dominant (Figure 2B, position 114), complete (Figure 2B, position
370), and transient (Figure 2B, position 419) amino acid
substitutions. A mutation was considered minor if its fraction was
less than or equal to 50% in the pool of viral quasispecies during
follow-up; e.g., a minor escape mutation is shown at position 186
in Figure 2B. A mutation was treated as dominant if its fraction
reached more than 50% in the pool of viral quasispecies but did
not reach complete substitution of original amino acid; e.g., a
dominant reverse mutation is shown at position 114 in Figure 2B.
A mutation was complete if it reached 100% in the pool of viral
quasispecies during the follow-up period; e.g., a complete escape
mutation is presented at position 370 in Figure 2B. A mutation was
considered transient if its frequency subsequently decreased below
100% for complete mutations, or below 50% for dominant
mutations, or if minor mutations disappeared over the observation
period; e.g, a minor transient mutation is outlined at position 419
in Figure 2B.
Based on the presence or absence of a particular viral variant in
the pool of viral quasispecies at the earliest available time point we
distinguished de novo (Figure 2C, position 146) and pre-existing
(Figure 2C, position 278) viral mutations. That a mutation is pre-
existing does not necessarily mean that it was transmitted because
early immune response may contribute to early viral diversification.
Of note, true de novo and pre-existing status of viral mutations can be
identified if sampling was performed at a very early time point, e.g.,
in Fiebig stage I or II before the earliest immune responses occur
[17,46]. Therefore, in this study identification of true de novo and
pre-existing state of viral mutations can be reliably applied to eight
cases of acute infection,but should be taken cautiouslyfor the subset
of 34 recently infected subjects, particularly for individuals sampled
in Fiebig stage V.
MHC Class I HLA Typing
High resolution HLA typing was performed on all 42 subjects
in the study using the AlleleSEQR HLA Sequencing-Based Typing
kit (Celera, Alameda, CA) according to the manufacturer’s in-
struction. Contig assembling and assignment of HLA alleles was
implemented by Assign SBT ver. 3.5.1.42 (Conexio Genomics,
Applecross, Australia). All ambiguous positions were resolved by re-
sequencing. Polymorphisms outside the targeted exons that could
not resolve heterozygote combinations are presented as HLA allele
variants in brackets or as two-digit HLA typing results.
Statistical Analysis
Timing data are summarized with medians (interquartile range
for 25% and 75%). If the number of viral mutations was sufficient
(n$3), comparisons of continuous outcomes between two groups
were based on Mann-Whitney Rank Sum tests. Cox proportional
hazards models with frailties were used to assess and compare the
time until different types of amino acid substitutions, while taking
into account correlations among timing data contributed by the
same subject. All reported p-values are 2-sided and not adjusted
for multiple analyses.
Nucleotide Sequence Accession Numbers
A total of 2,522 gag sequences generated in this study were
deposited in GenBank. The accession numbers are GQ275380–
GQ277569, GQ375107–GQ375128, and GQ870874–GQ871183.
Results
Heterogeneous Evolution of Gag Quasispecies in HIV-1
Subtype C Infected Subjects
All analyses in this study were performed using the cohort of 42
subjects with estimated time of seroconversion. Figures 3 to 5
exemplify the evolution of in vivo Gag mutations per amino acid
position in three subjects identified with acute HIV-1 subtype C
infection. In addition, Figures S2, S3, S4, S5, S6 show evolution of
in vivo Gag mutations in five other acutely infected subjects, and
Figures S7 and S8 show alignments of translated amino acids for
two acutely infected subjects, D-5018 and E-3430, respectively.
Data from 34 recently infected subjected is not shown, although all
the data were included in the analyses. The following three
examples highlight a remarkable heterogeneity in the evolution of
in vivo Gag mutations between subjects during the early phase of
HIV-1 subtype C infection.
Kinetics of viral RNA load, proviral DNA load, and CD4+ T cell
count in subject D-5018 arepresented in Figure 3A, while dynamics
of Gag mutations are shown in Figures 3B (reverse mutations), 3C
(escape mutations from consensus), and 3D (escape from non-wild
type). A dramatic fluctuation of CD4+ T cell count around 100 days
p/s (Figure 3A) coincided with dynamic changes in the spectrum of
viral quasispecies associated with reverse mutations to the wild type
(Figure 3B; amino acid positions 215, 389, and 453) and escape
mutations from the wild type (Figure 3C; amino acid positions 35,
142, 146, 370, and 428). Viral RNA load in subject D-5018
remained high at the level of 5.0 log10 copies/ml for about a year
p/s. Viral load was reduced about 1.0 log10 around 400 days p/s,
and was accompanied by reverse mutations at Gag positions 207,
292, 451 (Figure 3B), escape mutations from the wild type at
positions 90 and 129 (Figure 3C), and escape mutations from non-
wild type at positions 186 and 223 (Figure 3D). However the
relationship between observed viral mutations and viral load
changes and their causality in subject D-5018 should be taken
cautiously without support of functional immunologic data. At Gag
position 90, the interplay of two amino acids was observed from day
6 p/s to day 483 p/s. At day 6 p/s, this amino acid position was
shared between Glu at frequency 0.97 and Lys at 0.03, but then the
frequency of Glu increased to1.0 at days 103, 148, 177,and 301 p/s
providing evidence for a complete reversion to wild type and
eliminating Lys from the pool of viral quasispecies. However at days
Gag Mutation Timing in HIV-1C
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respectively. Dynamics of viral quasispecies at position 90 revealed a
phenomenon of reverse mutation to wild type virus followed by
escape mutation from the wild type. Interestingly, some of the
dominant mutations lost their dominance at later time points,
although as is evident from the example of subject D-5018, timing of
loss was unique for each amino acid position (Figure 3). Leu at
position215inp24wasaminoraminoacid atfrequency0.14 byday
6 p/s, and its fraction increased to 0.86, suggesting a dominance at
day 103 p/s. However the fraction of Leu was gradually reduced to
0.71, 0.56, 0.45, 0.45, and 0.38 at days 148, 177, 301, 393, and
483 p/s, respectively, suggesting a balance being established
between Leu and Val at later time points. Ile at position 389 located
in the p7 region of Gag stayed at frequency 0.21 by day 6 p/s,
reached 0.71 at day 103 p/s, and maintained dominance at day
148 p/s, but then dropped to 0.44, 0.36, 0, and 0.50 at days 177,
301, 393, and 483 p/s, respectively, also suggesting a balance
between Ile and Thr similar to the scenario seen at position 215.
Anotherpre-existingmutationatposition453inp6,Pro,waspresent
atfrequency 0.07 byday 6 p/sand increased to0.71 at day 103 p/s,
but then lost dominance at day 148 p/s, and balanced with initially
dominant Ser at a later time point. The similarities between
mutation patterns observed at positions 215, 389, and 453 in subject
D-5018 are intriguing, and warrant further studies to reveal the
underlying mechanism of the balancing of different amino acids. A
dynamic interplay between viral quasispecies at position 370
provides evidence that a sequential escape and reversion in Gag is
not a rare event during the first year of HIV-1 subtype C infection
(Figure 3). A minor pre-existing Thr was observed at frequency 0.07
at day 6 p/s but accounted for 1.0 at day 103 p/s, demonstrating a
successful complete escape from the wild type Ala. However the Thr
frequency gradually declined and was completely substituted by the
wild type-matching Ala by day 301 p/s, exemplifying a complete
escape followed by a complete reversion to the wild type. Val, the de
Figure 3. Temporal relationships between frequency distributions of Gag quasispecies in acutely infected subject D-5018 from day
6 p/s to day 483 p/s. MHC class I HLA profile is presented at the top of the figure. Gray bars at the background of each graph delineate 100-days
time intervals for better comparison between dynamics of viral load/CD4 (Figure 3A), and time of Gag mutations (Figures 3B to 3D). Number with the
letter at the top of each graph in B, C, and D represents amino acid position in Gag according to the HXB2 numbering (http://www.hiv.lanl.gov/) and
the most frequent amino acid in the HIV-1 subtype C consensus. Green circled R with arrow delineates reverse mutation to wild type virus, and red
circled E with arrow indicates escape mutations from wild type. A: Dynamics of plasma RNA load (red squares), proviral DNA load (green diamonds),
and CD4+ T cell count (blue triangles) over the follow up period. B: Reverse mutations to HIV-1 subtype C wild type virus. C: Escape mutations from
HIV-1 subtype C wild type virus. D: Escape mutations from non-wild type (wild type amino acid is not involved).
doi:10.1371/journal.pone.0007727.g003
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appeared at day 301 p/s and gradually reached 1.0 in the pool of
viralquasispeciesbyday 483 p/s,suggestinga potential contribution
of this mutation to viral fitness.
In contrast to subject D-5018, subject E-3430 dropped viral RNA
load below 400 copies/ml within 30 days p/s, but also demon-
strated increase of viral load accompanied by CD4+ T cells drop
around 200 days p/s (Figure 4A). Subject E-3430 had a relatively
high number of reverse mutations to HIV-1 subtype C wild type
(Figure 4B), suggesting a viral transmission from a genetically
distinct partner. Most reverse mutations to wild type in subject E-
3430 occurred early and were pre-existing, resulting in a quick
elimination of alternative amino acids from the pool of viral
quasispecies (e.g., amino acid positions 42, 92, 141, 151, 298, 341,
411, 412, 414, 431, 443, 449, 459, and 462 in Figure 4B). The
increase of viral RNA load around 200 days p/s was accompanied
by escape mutations from wild type such as at amino acid positions
147 and 441 (Figure 4C), and escape mutation from non-wild type
at position 28 (Figure 4D). Similarly to subject D-5018, the causality
intherelationship between viral mutationsand viralload changes in
subject E-3430 should be taken cautiously, and might require
support of immunologic analysis in future studies. At amino acid
position 111 in p17, the de novo reversion to Ser appeared at
frequency 0.10 at day 274 p/s on the background of interplay of
two other amino acids, Cys and Gly (Figure 4B). However Ser was
gone by day 305 p/s suggesting that the wild type-matching viral
variant did not have a replication advantage in the host
environment of subject E-3430. At position 441 in p1, the de novo
His-to-Tyr substitution resulted in a complete escape from the wild
type at days 243 p/s and 274 p/s, and was followed by minor
reversion of His at days 305, 339, and 404 p/s, apparently
suggesting immune suppression of the wild type variant. A mutation
at position 147 in p24 demonstrated a fast Ile-to-Leu escape that
appearedat day150 p/sand reached completenessby day274 p/s.
There was a sequential escape-reversion-escape series at position
374 in p2 from day 274 p/s to day 404 p/s. An unusual double
escape was observed at position 375 in p2 demonstrating a complex
sequential escape(Lys)-escape(His)-reversion(Asn)-escape(Lys)-re-
version(Asn) pattern. The de novo minor Lys at position 375
appeared at day 150 p/s, and was followed by the appearance of
His as a dominant amino acid at frequency 0.67 at day 243 p/s,
leaving Lys and Asn at frequency 0.17 each. However the spectrum
of viral quasispecies changed to Asn at 0.60, Lys at 0.30, and His at
0.10 at day 274 p/s. The interplay between viral quasispecies
resulted in a loss of His by day 305 p/s accompanied by sequential
switching of Lys and Asn frequencies at later time points.
Figure 4. Temporal relationships between frequency distributions of Gag quasispecies in acutely infected subject E-3430 from day
30 p/s to day 404 p/s. See legend to Figure 3.
doi:10.1371/journal.pone.0007727.g004
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dropped about 2.0 log10 within the first two months p/s, stayed
relatively low, but then increased around 200 days p/s (Figure 5A).
The increase in viral load coincided with a few reverse mutations
to wild type at positions 114 and 302 (Figure 5B) and escape
mutations from the wild type at amino acid positions 242 and 370
(Figure 5C). However functional immulogic studies are necessary
to resolve causality in the relationship between viral mutations and
viral load in subject F-3505. The reverse mutation at position 146
(Ser-to-Ala) at day 323 p/s was followed by a minor escape
mutation (Pro at frequency 0.25) at day 447 p/s. Escape mutations
from the wild type at positions 242, 252, and 370 gradually
reached dominance and were completed by days 323, 447, and
323 p/s, respectively. Two sequential transient escape mutations
from the wild type were evident at position 244. Ser appeared at
frequency 0.17 at day 203 p/s but disappeared by day 261 p/s,
while Ala appeared at frequency 0.14 at day 261 p/s and
disappeared by day 323 p/s. Similar sequential transient escapes
from the non-wild type occurred at position 182: Pro at frequency
0.13 was evident at day 98 p/s but gone at day 203 p/s, and was
followed by Lys at 0.14 at day 261 p/s that also disappeared by
day 323 p/s.
Timing of Amino Acid Substitutions in Gag
To address the timing of Gag mutations in relation to estimated
seroconversion, three analytical approaches were taken. First, the
time of amino acid substitutions in Gag was analyzed cumulatively
by type of mutation irrespective of the individual contribution by
each subject, providing an overall summary of the time and timing
differences between different types of mutations. Second, time to
specific Gag mutations were analyzed by fitting the Cox
proportional hazards models with frailties, which allowed for
correlation among data points contributed by each subject. Lastly,
the timing of reverse and escape mutations in Gag were analyzed
within individuals.
Table 1 summarizes the timing of first appearance, dominance,
completeness, and loss of mutations among two types of Gag
mutations, reverse mutations and escape mutations from the wild
type. The appearance of Gag mutations was analyzed overall and
within subsets of minor, transient, dominant, and complete
Figure 5. Temporal relationships between frequency distributions of Gag quasispecies in acutely infected subject F-3505 from day
7 to 447 days p/s. See legend to Figure 3. Amplicons from time points from day 70 p/s to day 323 p/s were amplified with alternative primers
which resulted in excluding the first 109 amino acids (HXB2 numbering; http://www.hiv.lanl.gov/) from analysis, and is reflected in the graphs at
amino acid positions 26 and 28 (Figure 5B), and 30 and 69 (Figure 5C).
doi:10.1371/journal.pone.0007727.g005
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than escape mutations from the wild type. The median (IQR) of the
first appearance of reverse mutations in Gag was 62 (44–139) days
p/s, while the median time of appearance of escape mutations from
the wild type was 234 (169–326) days p/s (p,0.001). The time of
appearance of minor mutations was 312 (160–418) days p/s and
349 (240–415) days p/s for reverse and escape mutations,
respectively (p=0.031), while appearance of transient mutations
did not differ significantly between reverse mutations and escape
mutations from the wild type. Among Gag mutations that reached
dominance, time to appearance of reverse mutations (median (IQR)
of 54 (30–78) days p/s) was significantly earlier than the appearance
of escape mutations from the wild type (median (IQR) of 104
(47–198) days p/s, (p,0.001). Similar timing relationships between
reverse and escape mutations were found for the appearance of Gag
mutations that became complete. The median (IQR) appearance of
reverse mutations that reached completeness was 54 (30–78) days
p/s, whereas the median appearance of escape mutations that
became complete later was 90 (44–196) days p/s (p=0.006). Time
until reaching dominance was significantly shorter for reverse
mutations (median (IQR) of 58 (44–105) days p/s) than for escape
mutations from the wild type (median (IQR) of 219 (90–326) days
p/s, p,0.001). A similar pattern was evident for mutations in Gag
that reached completeness. The medians (IRQ) of completeness
were152 (100–176) days p/sand 243(101–370)daysp/sforreverse
mutations and escape mutations from the wild type, respectively
(p=0.001). Therefore, based on multiple comparisons, we conclude
that reverse mutations in Gag occur significantly earlier than escape
mutations from the wild type.
The number of escape mutations from non-wild type was too
small for analysis within subsets, and therefore only major groups
were included in the comparative analysis. The time of first
appearance of escape mutations from the non-wild type (median
(IQR) of 188 (103–309) days p/s) was later than that of reverse
mutations (p,0.001) but earlier than that of escape mutations
from the wild type (p,0.001). The time of reaching dominance for
escape mutations from non-wild type (median (IQR) of 230 (150–
389) days p/s) was later than that for reverse mutations (p,0.001),
but did not significantly differ from the time to dominance for
escape mutations from the wild type (p=0.14). Time to
completeness for escape mutations from non-wild type (median
(IQR) of 243 (211–427) days p/s) was significantly longer than for
reverse mutations (p=0.001) but did not differ from escape
mutations from the wild type (p=0.27).
To address whether timing of Gag mutations is associated with
their presence in the pool of viral quasispecies at the earliest time
point, we analyzed the timing of reverse and escape mutations by
whether the mutations were pre-existing or de novo mutations
(Table 2). We note that most reverse mutations were pre-
existing while most escape mutations evolved de novo. The time of
appearance of the total reverse mutations and escape mutations
from the wild type did not significantly differ within subset of the
de novo mutations (p=0.16), but was shorter for pre-existing reverse
(p=0.044) mutations in Gag. For the de novo mutations, appearance
of reverse mutations that reached dominance (median of 113 days)
occurred significantly earlier than appearance of escape mutations
from the wild type (median of 174 days, p=0.041). In contrast, for
the pre-existingmutations, the appearance of reverse mutations that
reached dominance (median of 52 days) occurred slightly later than
appearance of escape mutations from the wild type (median of 44
days) but did not reach statistical significance (p=0.072). Similar
patterns werefound for appearance of reverseand escapemutations
that reached completeness (Table 2; p=103 and p=0.022 for
denovo and pre-existing mutations, respectively).Time until reaching
dominance or time to completeness did not differ between reverse
and escape mutations within either de novo or pre-existing mutations
in Gag.
Taking into account the correlation among an individual
subject’s values, we fit a Cox proportional hazards models with
frailties to compare time to first appearance (dominance, or com-
pleteness) for reverse mutations and escape mutations from the wild
type. The number of escape mutations from non-wild type was
small, and therefore not included in the comparative analysis. Time
of first appearance of reverse mutations occurred significantly
earlier than for escape mutations from the wild type (hazard ratio
(HR): 2.6; 95% CI: 2.3–3.0). Also, reverse mutations took sig-
nificantly less time to reach dominance (and completeness) as
compared to escape mutations from the wild type (for dominance:
HR 4.8 (3.4–6.8)); for completeness: HR 3.6 (2.3–5.5)). These
analysesprovidefurtherevidencethatreverse mutationsinGagtake
place at earlier times than do escape mutations from the wild type.
The number of reverse mutations per subject (median (IQR): 7
(4–13)) was smaller than the number of escape mutations from the
wild type (median (IQR): 16 (12–23); p,0.001). Reverse mutations
appeared in Gag significantly earlier than did escape mutations
from the wild type in 22 of 42 (52.4%) comparable subjects. In the
remaining 20 cases, there was no significant difference between
times of appearance. The median (IQR) time of first appearance of
Table 1. Timing of reverse mutations and escape mutations from the wild type in Gag during primary HIV-1 subtype C infection.
Reverse mutations
Escape mutations from
the wild type
p-value* for timing
comparison
n
Time, days p/s,
median (IQR) n
Time, days p/s,
median (IQR)
Time of Appearance: all mutations 353 62 (44; 139) 738 234 (169; 326) ,0.001
Minor mutations (did not reach dominance and were not lost) 57 312 (160; 418) 233 349 (240; 415) 0.031
Transient minor mutations (did not reach dominance and were
lost by 500 days p/s)
39 196 (116; 252) 438 219 (152; 261) 0.250
Mutations that reached dominance 257 54 (30; 78) 67 104 (47; 198) ,0.001
Mutations that reached completeness (fixed) 209 54 (30; 78) 39 90 (44; 196) 0.006
Time of Dominance: mutations that reached dominance 257 58 (44; 105) 67 219 (90; 326) ,0.001
Time of Completeness: mutations that reached completeness (fixed) 209 152 (100; 176) 39 243 (101; 370) 0.001
*Mann-Whitney Rank Sum Test.
doi:10.1371/journal.pone.0007727.t001
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first appearance of escape mutations from the wild type was
236 (198–261) days, providing further support for the identified
timing pattern in the evolution of different types of Gag mutations.
Fewer comparisons were available for the intra-patient analysis of
timeto dominanceandcompletenessbecausemostescapemutations
from the wild type never exceeded the level of 50% in the pool of
viral quasispecies. Shorter time to dominance for reverse mutations
was observed in 6 of 23 (26%) comparable subjects. The time to
dominance of reverse mutations (median (IQR) of 58 (29–152) days)
was significantly shorter than that of escape mutations from the wild
type (median (IRQ) of 197 (136–286) days, p,0.001). Time to
completeness for reverse mutations (median (IRQ) of 146 (102–204)
days) was significantly shorter than that for escape mutations from
the wild type (median (IRQ) of 244 (124–329) days, p=0.018).
Timing of Mutations across Gag Cleavage Products
We assessed whether the timing of Gag mutations differs between
Gag cleavage products by performing analyses within p17, p24, and
p2p7p1p6 (Tables 3, 4,5).In allanalyzed regions, reversemutations
appeared faster than escape mutations from the wild type (Figure 6).
However, the magnitude of association between time to first
appearance and mutation type varied according to the Gag
cleavage product in which the mutations occurred (interaction test,
p=0.008), as did the association between time to completeness and
mutation type (interactiontest, p=0.02).In contrast, the association
between time to dominance and mutation type did not vary
significantly across Gag cleavage products (interaction test, p=0.2);
neither did the association between time to completeness and
mutation type (interaction test, p=0.2).
Discussion
Timing patterns of viral mutational pathways in the natural
course of HIV-1 infection are not well understood, and denote a
knowledge gap in HIV research. In this study, we addressed timing
of in vivo Gag mutations during primary HIV-1 subtype C infection
in a prospective cohort of 8 acutely and 34 recently infected
individuals from Botswana. Despite a significant heterogeneity
between subjects in the time of appearance, dominance, and
completeness of amino acid substitutions in Gag during the early
phase of HIV-1 subtype C infection, we found that the in vivo
reverse mutations to the wild type in Gag occurred significantly
earlier than escape mutations from the wild type.
Our results show that the appearance, dominance, and
completeness of reverse mutations in Gag occurs significantly
sooner than escape mutations from the wild type, which is
consistent with a recent report [2]. It is believed that reverse
mutations restore the wild type viral sequence, and apparently
account for more fit virus with higher replication potential.
However the question ‘‘When do viral mutations occur?’’ has not
been addressed by previous studies. Our finding that reverse
mutation in Gag appears at a median of 62 days following
seroconversion may have important public health implications, as
it may suggest the existence of a ‘‘window of opportunity’’ for early
interventions of about two months after seroconversion.
Early initiation of antiretroviral therapy in those subjects who
maintain high viral load might slow down viral reversions by
reducing viral replication. Our results provide a rationale for
testing a hypothesis that early therapeutic vaccination (e.g., within
two months p/s) may prevent reverse mutations and reduce
viral set point. The amino acid positions that undergo frequent
Table 2. De novo and pre-existing reverse mutations and escape mutations from the wild type in Gag during primary HIV-1
subtype C infection.
Reverse mutations
Escape mutations from the
wild type
p-value* for timing
comparison
n
Time, days p/s,
median (IQR) n
Time, days p/s,
median (IQR)
Time of Appearance:
De novo mutations 113 223 (137; 345) 696 235 (181; 326) 0.159
Pre-existing mutations 240 52 (30; 78) 42 65 (44; 226) 0.044
Mutations that reached dominance:
De novo mutations 30 113 (58; 205) 42 174 (105; 233) 0.041
Pre-existing mutations 227 52 (28; 65) 26 47 (7; 52) 0.072
Mutations that reached completeness (fixed):
De novo mutations 17 139 (46; 184) 23 170 (94; 203) 0.103
Pre-existing mutations 193 52 (30; 65) 17 46 (7; 50) 0.022
Time of Dominance:
De novo mutations 33 223 (117; 264) 43 261 (2072; 349) 0.074
Pre-existing mutations 227 58 (30; 103) 26 92 (44; 177) 0.104
Mutations that reached completeness (fixed):
De novo mutations 17 139 (55; 230) 23 240 (113; 260) 0.092
Pre-existing mutations 193 58 (30; 79) 16 48 (26; 92) 0.608
Time of Completeness:
De novo mutations 17 204 (139; 241) 23 323 (228; 377) 0.052
Pre-existing mutations 193 152 (100; 174) 17 139 (100; 294) 0.365
*Mann-Whitney Rank Sum Test.
doi:10.1371/journal.pone.0007727.t002
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mutations occur denotes the opportunity to prevent these
mutations. If the vaccine can abrogate or at least slow down
reverse mutations, the level of viral replication could be reduced,
allowing more time for the immune system to regain adequate
immune response.
The current study generates a number of other hypotheses that
can be addressed in future studies. It would be important to
determine relationships between observed Gag mutations and
virus-specific CD8+ and CD4+ T cell responses. Timing of virus-
specific T cell responses is critical for understanding whether
immune responses drive or follow viral mutations. It would be
crucial to determine whether ART affects the timing of viral
mutational pathways in Gag, and if so, the extent of ART
contribution. Knowledge of timing patterns of co-variation and
compensatory mutations in Gag could further facilitate our
understanding of viral evolution in the early phase of HIV-1
infection. In contrast to the cross-sectional studies, the current
study focuses on multiple time points assuming that functionally
relevant viral variants should be detectable in a set of longitudinal
samples even with a relatively small number of viral sequences per
time point. Conversely, if viral variants are not detectable in
longitudinal sampling, its functional relevance may be low.
The results of our studies seem to resolve the discrepancy in
understanding of relationships between HIV-1 reverse mutations
to and escape mutations from the wild type sequence highlighted
recently by Brumme & Walker [54]. Our data are congruent with
recent studies [2,17,55,56], and demonstrate that after serocon-
version, the overall number of reverse mutations is smaller than
the number of escape mutations, but reverse mutations occur
earlier and are mostly dominant or complete, while escape
mutations from the wild type occur later and most are transient.
In case of transmissionof multiple or closelyrelated viral variants,
the selection of one viral population over time was not uncommon.
The observed pattern suggesteda transmission ofmore than a single
viral variant, although we cannot exclude transmission of a single
variant followed byearlydiversificationinresponsetoearlyimmune
responses as described recently by Goonetilleke et al. [17].
Irrespective of the origin of viral mutation, the presence of two (or
multiple) amino acids at an early time point followed by a selection
of one viral population is an important phenomenon because it
shortens the time to reach dominanceand completenessof the more
fit virus. For example, we found that the time to a complete T242N
escape in well-studied epitope TW10 [13,52,53,57,58] is shorter in
subjects infected with a mix of Thr and Asn than in individuals
infected with the wild type virus only (unpublished data).
Table 3. Time to 1
st appearance of amino acid substitutions by Gag cleavage product.
Gag mutations
Reverse Escape from wild type
Gag cleavage product n Time, median (IQR) n Time, median (IQR) HR, 95% CI
p17 92 88 (44–206) 171 227 (150–350) 2.1 (1.6–2.8)
p24 107 62 (44–102) 235 235 (180–325) 5.0 (3.7–6.6)
p2p7p1p6 154 62 (44–141) 332 235 (169–317) 2.8 (2.2–3.4)
doi:10.1371/journal.pone.0007727.t003
Table 4. Time to Dominance of amino acid substitutions by Gag cleavage product.
Gag mutations
Reverse Escape from wild type
Gag cleavage product n Time, median (IQR) n Time, median (IQR) HR, 95% CI
p17 59 58 (44–164) 18 212 (138–311) 3.0 (1.5–6.0)
p24 92 62 (30–88) 16 237 (48–302) 7.3 (2.9–18.8)
p2p7p1p6 109 62 (44–122) 35 219 (90–334) 5.6 (3.3–9.7)
doi:10.1371/journal.pone.0007727.t004
Table 5. Time to Completeness of amino acid substitutions by Gag cleavage product.
Gag mutations
Reverse Escape from wild type
Gag cleavage product n Time, median (IQR) n Time, median (IQR) HR, 95% CI
p17 36 152 (127–233) 9 349 (295–377) 2.2 (0.9–5.2)
p24 77 152 (95–170) 11 274 (170–329) 10.4 (3.0–36.2)
p2p7p1p6 97 147 (108–204) 20 228 (98–340) 3.0 (1.6–5.6)
doi:10.1371/journal.pone.0007727.t005
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type are compared to escape mutations from the wild type.
doi:10.1371/journal.pone.0007727.g006
Gag Mutation Timing in HIV-1C
PLoS ONE | www.plosone.org 12 November 2009 | Volume 4 | Issue 11 | e7727The study identified timing of different types of in vivo Gag
mutations in primary HIV-1 subtype C infection in relation to the
estimated time of seroconversion by using a novel approach of
direct mapping of Gag mutations along the timeline of HIV-1
infection. Overall, the in vivo reverse mutations to the wild type
occurred significantly earlier than escape mutations from the wild
type. This shorter time to incidence of reverse mutations remained
in the subsets of in vivo Gag mutations that reached dominance or
completeness.
Supporting Information
Figure S1 Time points post-seroconversion (p/s) and the
number of sequences. Patient ID and abbreviated code are shown
in the first two columns, and are followed by the Fiebig stage of
each subject. The distribution of 42 cases by Fiebig staging
included 8 (19%) cases in stage II; 10 (24%) cases in stage IV; 18
(43%) cases in stage V; and 4 (10%) cases on the edge of stages V
and VI (extremely faint p31 band evident for a transition from
stage V to stage VI). According to the original paper [35] and
application of Fiebig staging to HIV-1 subtype C samples,[59] the
assumption was made that the beginning of Fiebig stage III
coincides with the time of detectable seroconversion (time 0), and
the mean duration of Fiebig stage III is 3 days, of stage IV is 6
days, and of stage V is 70 days. Based on these estimates, the time
from seroconversion until detection was assumed to average 6 days
for subjects in stage IV (3 days of phase III and 3 days to the mid-
point of phase IV), 44 days for subjects in stage V (9 days of phases
III and IV and 35 days to the mid-point of phase V), and 79 days
for stage V/VI (9 days of phases III and IV, and 70 days of phase
V). Time points from seroconversion are shown for each subjects
as day post-seroconversion, p/s with corresponding number of gag
sequences generated in the study. The color-coding scheme is
presented at the top of the figure. Sequences obtained from viral
RNA template are delineated by pink, sequences generated from
proviral DNA template are shown without highlight, and the
cumulative number of sequences acquired from both RNA and
DNA template are highlighted by dark red. The total number of
gag sequences generated in the study is shown at the bottom right.
Found at: doi:10.1371/journal.pone.0007727.s001 (0.08 MB EPS)
Figure S2 Temporal relationships between frequency distribu-
tions of Gag quasispecies in acutely infected subject A-1811 at 10
time points from day 6 p/s to day 356 p/s. MHC class I HLA
profile is presented at the top of the figure. Gray bars at the
background of each graph delineate 100-days time intervals for
better comparison between dynamics of viral load/CD4 (Figure
S2.A), and time of Gag mutations (Figure S2.B to S2.D). Number
with the letter at the top of each graph in B, C, and D represents
amino acid position in Gag according to the HXB2 numbering
(http://www.hiv.lanl.gov/) and the most frequent amino acid in
the HIV-1 subtype C consensus. Green circled R with arrow
delineates reverse mutation to wild type virus, and red circled E
with arrow indicates escape mutations from wild type. A:
Dynamics of plasma RNA load (red squares), proviral DNA load
(green diamonds), and CD4+ T cell count (blue triangles) over the
follow up period. Time of ART initiation is outlined by dashed
arrow. B: Reverse mutations to HIV-1 subtype C wild type virus.
C: Escape mutations from HIV-1 subtype C wild type virus. D:
Escape mutations from non-wild type (wild type amino acid is not
involved).
Found at: doi:10.1371/journal.pone.0007727.s002 (1.95 MB EPS)
Figure S3 Temporal relationships between frequency distribu-
tions of Gag quasispecies in acutely infected subject B-2865 from
day 10 p/s to day 223 p/s. See legend to Figure S2.
Found at: doi:10.1371/journal.pone.0007727.s003 (1.62 MB EPS)
Figure S4 Temporal relationships between frequency distribu-
tions of Gag quasispecies in acutely infected subject C-3312 from
day 4 p/s to day 445 p/s. See legend to Figure S2. No escape
mutations from non-wild type were detected in subject C-3312 (no
Figure S4.D is presented).
Found at: doi:10.1371/journal.pone.0007727.s004 (1.69 MB EPS)
Figure S5 Temporal relationships between frequency distribu-
tions of Gag quasispecies in acutely infected subject G-3603 from
day 4 p/s to day 345 p/s. See legend to Figure S2.
Found at: doi:10.1371/journal.pone.0007727.s005 (1.50 MB EPS)
Figure S6 Temporal relationships between frequency distribu-
tions of Gag quasispecies in acutely infected subject H-5582 from
day 16 p/s to day 347 p/s. See legend to Figure S2.
Found at: doi:10.1371/journal.pone.0007727.s006 (1.46 MB EPS)
Figure S7 Alignment of translated amino acids in subject D-
5018 at 7 time points from day 6 p/s to day 483 p/s. Sampling
time of sequences is outlined in sequence name, and is shown in
days p/s as a 3-digit number after the abbreviated patient code
‘‘D_’’. For example, D_006_01 delineate sampling at day 6 p/s,
sequence number 1, D_103_02 outlines sampling at day 103 p/s,
sequence number 2, etc. Sequences originating from viral RNA
template are delineated with ‘‘RNA’’ at the end of sequence name,
while all other sequences were generated from proviral DNA
template. Shown sequences are compared to the first sequence in
alignment. Note that numbering above alignment represents
sequences in subject D-5018, and does not correspond to Gag
amino acid numbering of HXB2.
Found at: doi:10.1371/journal.pone.0007727.s007 (0.11 MB EPS)
Figure S8 Alignment of translated amino acids in subject E-
3430 at 8 time points from day 30 p/s to day 404 p/s. Sampling
time of sequences is outlined in sequence name, and is shown in
days p/s as a 3-digit number after the abbreviated patient code
‘‘E_’’. For example, E_030_01 delineate sampling at day 30 p/s,
sequence number 1, E_059_01 outlines sampling at day 59 p/s,
sequence number 1, etc. Sequences originating from viral RNA
template are delineated with ‘‘RNA’’ at the end of sequence name,
while all other sequences were generated from proviral DNA
template. Shown sequences are compared to the first sequence in
alignment. Note that numbering above alignment represents
sequences in subject E-3430, and does not correspond to Gag
amino acid numbering of HXB2.
Found at: doi:10.1371/journal.pone.0007727.s008 (0.12 MB EPS)
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